Glenmark Pharmaceuticals's latest lobbying report covers Q2 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $40K. Its first report covers Q4 2022; the issues it reports most are Health Issues.

Glenmark Pharmaceuticals

Latest quarter: No record; Q3 2026 · 0 reports
Last 12 months: $40K; Last 4 quarters
vs last quarter: −100.0%; Q3 2026 against the quarter before
First report: Q4 2022; The first quarter a report named it

Lobbying by quarter

Glenmark Pharmaceuticals lobbying by quarter
Quarter	Amount	Reports
Q4 2022	$0	1
Q1 2023	$0	1
Q2 2023	$0	1
Q3 2023	$0	1
Q4 2023	$0	1
Q1 2024	$0	1
Q2 2024	$0	1
Q3 2024	$0	0
Q4 2024	$0	0
Q1 2025	$0	0
Q2 2025	$0	0
Q3 2025	$0	0
Q4 2025	$0	0
Q1 2026	$20K	1
Q2 2026	$20K	1
Q3 2026	$0	0

By issue

Health issues$40K · 2 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

HOUSE OF REPRESENTATIVES2 reports
SENATE2 reports

Firms it paid

Firm
Bose Public Affairs Group	$40K	2 quarters
In-houseGlenmark Pharmaceuticals USA	$0	7 quarters

Former officials lobbying for it

	Former position	Firm
DAVID CRANE	Senior Policy Advisor, Senate Majority Leader, Senate Republican Leader, Professional Staff, Senate Commerce Committee, Legislative Director, Senator Dan Coats, Legislative Assistant Senator Dan Coats	Bose Public Affairs Group	Q2 2026

Lobbying reports

	Filed by		Issues
07/20for Q2	Bose Public Affairs Group	$20K	Health issues
04/20for Q1	Bose Public Affairs Group	$20K	Health issues
04/17for Q1	Bose Public Affairs Group	Under $5,000	Health issues
24/09/24for Q2 2024	In-house	Under $5,000
24/04/01for Q1 2024	In-house	Under $5,000
24/02/05for Q4 2023	In-house	Under $5,000
23/10/16for Q3 2023	In-house	Under $5,000
23/07/04for Q2 2023	In-house	Under $5,000
23/06/26for Q1 2023	In-house	Under $5,000
23/04/18for Q1 2023	In-house	Under $5,000
23/03/15for Q4 2022	In-house	Under $5,000